Stress and Parkinson’s disease: from dysfunctional detection to impaired handling: a narrative review.

Publication date: Sep 24, 2026

Stress can precipitate Parkinson’s disease (PD), and conversely, PD imposes substantial stress on affected individuals. Controlled studies support this bidirectional relationship. Recent observations during the Covid-19 pandemic suggested that PD patients may sometimes display an unexpected resilience to stressful events (SE), in particular in terms of missing motor deterioration. However, this “favorable” interpretation can be misleading as PD is characterized by dysfunctional stress detection and stress processing. Furthermore, reduced stress-related cardiac morbidity has not been demonstrated uncontestably. Indeed, detailed analyses indicate that involvement of non-dopaminergic systems modifies-rather than mitigates-stress responses. Lewy body pathology already compromises activation of the hypothalamic-pituitary-adrenal (HPA) axis, while autonomic cardiac responses are blunted. Dysfunction of the superior colliculi impairs instant detection of stress events (SE); degeneration of the pedunculopontine nucleus disrupts appropriate motivational appraisal of the SE. Impaired contrast discrimination and olfaction hinder immediate perceptual SE assessment. Locus coeruleus involvement reduces alertness, further limiting SE evaluation. Finally, at the nexus of stress handling, dysfunctional amygdalar networks contribute to diminished autonomic reactivity and altered emotional processing. This review synthesizes current knowledge on peripheral and central stress-related systems affected by PD pathophysiology. It outlines established, emerging, and theoretical therapeutic strategies, including approaches informed by the Stress Reduction Theory and the Attention Restoration Theory. It underscores the need for systematic investigation into stress mechanisms in PD, an area that remains insufficiently explored.

Open Access PDF

Concepts Keywords
Dopaminergic Amygdala
Parkinson COVID-19
Pathophysiology Locus coeruleus
Substantial Parkinson’s disease
Vienna Stress
Superior colliculi

Semantics

Type Source Name
disease MESH Parkinson’s disease
disease MESH Covid-19 pandemic
disease MESH chl
disease MESH LIH
drug DRUGBANK Trestolone
disease MESH neurodegenerative diseases
pathway REACTOME Neurodegenerative Diseases
disease MESH syndrome
drug DRUGBANK Serotonin
drug DRUGBANK gamma-Aminobutyric acid
disease MESH physical trauma
disease MESH posttraumatic stress disorder
disease MESH death
drug DRUGBANK Glutamic Acid
disease MESH PTSD
drug DRUGBANK Aminolevulinic acid
drug DRUGBANK Corticotropin
drug DRUGBANK Corticorelin
disease MESH anxiety
drug DRUGBANK Norepinephrine
drug DRUGBANK Hydrocortisone
disease MESH hypertrophy
drug DRUGBANK Dopamine
disease MESH parkinsonian syndromes
disease MESH REM sleep behavior disorder
disease MESH dementia
drug DRUGBANK Trihexyphenidyl
drug DRUGBANK Profenamine
disease MESH car
disease MESH hypotension
disease MESH face
disease MESH depressive syndromes
disease MESH neuroinflammation
drug DRUGBANK Tretamine
drug DRUGBANK Cortisone
disease MESH anhedonia
disease MESH cardiovascular diseases
drug DRUGBANK Iobenguane
disease MESH prodromal syndrome
disease MESH atrial fibrillation
disease MESH myocardial infarction
disease MESH ers
disease MESH Lewy body dementia
drug DRUGBANK Esomeprazole
disease MESH dys
disease MESH daytime sleepiness
drug DRUGBANK Indoleacetic acid
disease MESH tremor
disease MESH sleepiness
pathway KEGG Cholesterol metabolism
drug DRUGBANK Piroxicam
disease MESH ganglion
pathway KEGG Circadian rhythm
disease MESH ame
disease MESH cognitive impairment
disease MESH ICD
disease MESH adjustment disorder
disease MESH bradykinesia
disease MESH Fahn
disease MESH inflammation
drug DRUGBANK L-Tryptophan
disease MESH pneumonia
disease MESH dysphagia
disease MESH delirium
disease MESH cytokine storm
disease MESH tic
disease MESH encephalopathy
disease MESH infection
disease MESH long COVID
disease MESH fatigue
disease MESH MDS
disease MESH fac
disease MESH insomnia
disease MESH constipation
disease MESH bed
drug DRUGBANK Isoxaflutole
disease MESH Alzheimer disease
pathway KEGG Alzheimer disease
disease MESH Movement Disorder
drug DRUGBANK Levodopa
disease MESH dyspnea
disease MESH mitochondrial dysfunction
disease MESH viral infections
disease MESH genetic susceptibility
drug DRUGBANK ANX-510
disease MESH CBT
disease MESH pain
drug DRUGBANK Dimercaprol
pathway REACTOME Reproduction
disease MESH included
drug DRUGBANK Coenzyme M
disease MESH sepsis
disease MESH neurologic disorders
drug DRUGBANK D-Alanine
pathway KEGG Parkinson disease
disease MESH Dis
disease MESH JPD
disease MESH coronary artery disease
disease MESH sleep disorders
disease MESH demyelinating diseases
disease MESH parasomnias
disease MESH traumatic brain injury
disease MESH visual hallucinations
disease MESH Park
disease MESH psychiatric disorders
drug DRUGBANK Tromethamine
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH lfs
disease MESH Impulse control disorders
pathway REACTOME Immune System
disease MESH multiple system atrophy
disease MESH progressive supranuclear palsy
disease MESH acp
disease MESH Stroke
disease MESH AEM
disease MESH alpha synuclein pathology
disease MESH aspiration pneumonia

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *